CRA was retained by the claimant in an arbitration regarding the breach of a license agreement relating to pharmaceutical manufacturing technology. In addition to quantifying damages, the CRA team also provided opinions relating to the value of market exclusivity for pharmaceuticals and the relative value of the licensed patented and non-patented intellectual property at issue in the case. Dr. Sean Sheridan submitted two expert reports and provided testimony in deposition and at the arbitration hearing.
Recent federal circuit opinions address the economic domestic industry requirement
Under Section 337, a complainant must demonstrate that a domestic industry relating to each asserted patent either exists or is in the process of being...